Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6356905 | 0.82 | ALDH1A1 (0.53) | POLBCHRM1GAAALDH1A1CHRM5 | |
| SCHEMBL477816 | 0.74 | DYRK3 (0.37) | CHRM1LMNASMN1; SMN2KMT2ATSHR | |
| SCHEMBL18488356 | 0.70 | HTR1A (0.43) | TEAD1ALDH1A1FAAHL3MBTL1KMT2A | |
| SCHEMBL24105172 | 0.69 | JAK2 (0.55) | TEAD1KDM4E | |
| SCHEMBL3068861 | 0.69 | JAK2 (0.55) | TEAD1KDM4E | |
| SCHEMBL9343895 | 0.69 | GAA (0.45) | CHRM1GAAALDH1A1CHRM5L3MBTL1 | |
| SCHEMBL9201481 | 0.68 | ALDH1A1 (0.50) | CHRM1GAAALDH1A1CHRM5L3MBTL1 | |
| SCHEMBL9474570 | 0.67 | TEAD1 (0.48) | TEAD1FAAH | |
| SCHEMBL9042581 | 0.66 | ALDH1A1 (0.43) | CHRM1ALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL20467369 | 0.66 | GAA (0.45) | POLBCHRM1GAAALDH1A1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411379-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-8318793-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| EP-2411379-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110003810-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010109005-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003810-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | TEAD1 3463/4885POLB 2146/4885CHRM1 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.